person · Reporting owner

STRECK PAUL

Disclosed activity across 4 companies

Tapewire entity: 62218
SEC CIK: 0001708063

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INSMED IncINSM · Entity 3174	Chief Medical Officer	August 08, 2018	August 09, 2018
PepGen Inc.PEPG · Entity 6253	EVP, Head of R&D	March 04, 2026	March 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INSMED Inc

Report date August 08, 2018 · Filed August 09, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,996	Reported balance After 2018-08-08 transaction · row 1 1 source row Row 1 · 2018-08-08 · Grant · Acquired 4,506 · Balance 15,996 F1: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2: Each Restricted Stock Unit was received as a grant on August 8, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant.

F2: Each Restricted Stock Unit was received as a grant on August 8, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock.

PepGen Inc.

Report date March 04, 2026 · Filed March 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	76,226	Ending reported balance After 2026-03-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-04 · Sale · Disposed 1,832 · Balance 76,273 F1: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Row 2 · 2026-03-04 · Sale · Disposed 47 · Balance 76,226 F1: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALBIREO PHARMA, INC.

Report date March 02, 2023 · Filed March 02, 2023

Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-03-02 · Disposition to issuer · Disposed 118,966 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").

F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").

F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;

F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.

F5: Not applicable.

ALDER BIOPHARMACEUTICALS INC

Report date October 22, 2019 · Filed October 24, 2019

Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2019-10-22 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-10-11 · Grant · Acquired 1,390 · Balance 1,390 F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c). Row 2 · 2019-10-22 · Disposition to issuer · Disposed 1,390 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.41 · Expires 2029-01-20	Direct	0	Reported balance After 2019-10-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-22 · Disposition to issuer · Disposed 250,000 · Balance 0 F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 21, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c).

F2: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.

F3: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.

F4: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 21, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.

F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 04, 2026 Filed Mar 6, 2026 16:14 UTC	PepGen Inc. PEPG · Entity 6253	SaleCommon Stock	47	$6.29	$295.54	Disclosure SEC source: 0001835597-26-000016 · form4.xml · nonDerivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,226 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document
March 04, 2026 Filed Mar 6, 2026 16:14 UTC	PepGen Inc. PEPG · Entity 6253	SaleCommon Stock	1,832	$6.23	$11,413.36	Disclosure SEC source: 0001835597-26-000016 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,273 F1 · kind: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units ("RSUs"). The mandatory sale of the Reporting Person's shares was provided for in a RSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. Read SEC document
March 01, 2026 Filed Mar 2, 2026 17:05 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	196,500	$0.00 Strike: $6.22	$0.00	Disclosure SEC source: 0001835597-26-000006 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
March 01, 2026 Filed Mar 2, 2026 17:05 UTC	PepGen Inc. PEPG · Entity 6253	GrantCommon Stock	50,300	$0.00	$0.00	Disclosure SEC source: 0001835597-26-000006 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,105 F1 · shares: Consists of 50,300 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
November 04, 2025 Filed Dec 18, 2025 15:33 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0001835597-25-000017 · form4.xml · derivative · entry 4 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,816 Underlying: Common Stock · 40,000 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
November 04, 2025 Filed Dec 18, 2025 15:33 UTC	PepGen Inc. PEPG · Entity 6253	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $9.83	$0.00	Disclosure SEC source: 0001835597-25-000017 · form4.xml · derivative · entry 3 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
November 04, 2025 Filed Dec 18, 2025 15:33 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	202,816	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0001835597-25-000017 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,816 Underlying: Common Stock · 202,816 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
November 04, 2025 Filed Dec 18, 2025 15:33 UTC	PepGen Inc. PEPG · Entity 6253	Disposition to issuerStock Option (Right to Buy) · Derivative	202,816	$0.00 Strike: $9.83	$0.00	Disclosure SEC source: 0001835597-25-000017 · form4.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 202,816 shares Expires 2034-08-18 F1 · kind: On November 4, 2025, the Issuer's Board of Directors approved a repricing of the Reporting Person's outstanding stock options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan. The exercise price of eligible options was reduced to $4.53, with all other terms unchanged except that the reduced exercise price is available only if the Reporting Person satisfies the applicable retention period; otherwise, the original exercise price will apply. The transactions reported herein are exempt pursuant to Rules 16b-6(d) and 16b-3 under the Securities Exchange Act of 1934. F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
May 30, 2025 Filed Jun 2, 2025 17:03 UTC	PepGen Inc. PEPG · Entity 6253	PurchaseCommon Stock	8,375	$1.24	$10,393.38	Disclosure SEC source: 0001127602-25-016227 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,805 F1 · price: Shares of Common Stock purchased pursuant to the PepGen Inc. 2022 Employee Stock Purchase Plan ("ESPP"), for the purchase period of December 1, 2024 to May 30, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of PepGen's Common Stock on May 30, 2025. Read SEC document
March 03, 2025 Filed Mar 5, 2025 17:30 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	87,000	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001127602-25-008365 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2035-03-02 F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document
March 03, 2025 Filed Mar 5, 2025 17:30 UTC	PepGen Inc. PEPG · Entity 6253	GrantCommon Stock	19,430	$0.00	$0.00	Disclosure SEC source: 0001127602-25-008365 · form4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,430 F1 · shares: .Consists of shares of Common Stock issuable under 19,430 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on March 3, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document
August 19, 2024 Filed Aug 20, 2024 16:28 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $9.83	$0.00	Disclosure SEC source: 0001127602-24-022610 · form4.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,816 Underlying: Common Stock · 40,000 shares Expires 2034-08-18 F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
August 19, 2024 Filed Aug 20, 2024 16:28 UTC	PepGen Inc. PEPG · Entity 6253	GrantStock Option (Right to Buy) · Derivative	202,816	$0.00 Strike: $9.83	$0.00	Disclosure SEC source: 0001127602-24-022610 · form4.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · EVP, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,816 Underlying: Common Stock · 202,816 shares Expires 2034-08-18 F1 · shares: The option has been granted pursuant to the PepGen Inc. 2024 Inducement Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document
March 02, 2023 Filed Mar 2, 2023 16:57 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	Disposition to issuerRestricted Stock Units · Derivative	118,966	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-014773 · doc4.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,966 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3 · price: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4 · price: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F2 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3 · derivative.exercise_date: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4 · derivative.exercise_date: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5 · derivative.expiration_date: Not applicable. Read SEC document
January 19, 2023 Filed Jan 25, 2023 20:07 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-004946 · doc4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,966 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, with the remainder vesting in equal installments every three months thereafter beginning on April 19, 2024 and ending on January 19, 2027. F2 · balance_after: Represents 118,966 restricted stock units. Read SEC document
January 19, 2023 Filed Jan 27, 2023 17:23 UTC Amendment	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	55,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-005331 · doc4a.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,966 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 19, 2024, 6.25% of the shares every three months thereafter beginning on April 19, 2024 and ending on January 19, 2025, and 12.5% of the shares every three months thereafter beginning on April 19, 2025 and ending on January 19, 2026. F2 · balance_after: Represents 118,966 restricted stock units. Read SEC document
December 19, 2022 Filed Dec 21, 2022 16:10 UTC	ALBIREO PHARMA, INC. ALBO · Entity 116015	GrantCommon Stock	63,966	$0.00	$0.00	Disclosure SEC source: 0001209191-22-062327 · doc4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,966 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs will vest as to 25% of the shares on December 19, 2023 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on March 19, 2024 and ending on December 19, 2026, subject to the employee's continued service with the issuer through the applicable vesting dates. F2 · balance_after: Represents 63,966 restricted stock units. Read SEC document
October 22, 2019 Filed Oct 24, 2019 19:28 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $13.41	$0.00	Disclosure SEC source: 0001209191-19-053944 · doc4.xml · derivative · entry 3 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2029-01-20 F2 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 21, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document
October 22, 2019 Filed Oct 24, 2019 19:28 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerCommon Stock	1,390	$18.00	$25,020.00	Disclosure SEC source: 0001209191-19-053944 · doc4.xml · nonDerivative · entry 2 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser"). On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F3 · price: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document
October 11, 2019 Filed Oct 24, 2019 19:28 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantCommon Stock	1,390	$9.20	$12,788.00	Disclosure SEC source: 0001209191-19-053944 · doc4.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390 F1 · kind: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan on October 11, 2019 in a transaction exempt under Rule 16b-3(c). Read SEC document
January 21, 2019 Filed Jan 23, 2019 17:23 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $13.42	$0.00	Disclosure SEC source: 0001209191-19-005019 · doc4.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-01-20 F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 21, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document
January 21, 2019 Filed Feb 1, 2019 17:32 UTC Amendment	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $13.41	$0.00	Disclosure SEC source: 0001209191-19-006549 · doc4a.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-01-20 F1 · derivative.exercise_price: The exercise price was incorrectly entered in the Reporting Person's original Form 4. F2 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 21, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document
August 08, 2018 Filed Aug 9, 2018 20:13 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	4,506	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-18-000054 · edgar.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,996 F1 · shares: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on August 8, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document
January 04, 2018 Filed Jan 8, 2018 21:10 UTC	INSMED Inc INSM · Entity 3174	GrantStock Option · Derivative	59,660	$0.00 Strike: $30.46	$0.00	Disclosure SEC source: 0001127430-18-000019 · edgar.xml · derivative · entry 2 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,660 Underlying: Common Stock · 59,660 shares Expires 2028-01-04 F3 · derivative.exercise_date: Stock options granted under the Company's 2017 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty-five percent (25%) on the first anniversary of the grant date and an additional twelve and one-half percent (12.5%) vest on the six month anniversary of the first anniversary date and each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
January 04, 2018 Filed Jan 8, 2018 21:10 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	11,490	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-18-000019 · edgar.xml · nonDerivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,490 F1 · shares: Restricted stock units granted pursuant to the Company's 2017 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2018, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document
June 05, 2017 Filed Jun 7, 2017 20:07 UTC	INSMED Inc INSM · Entity 3174	GrantStock Option · Derivative	109,210	$0.00 Strike: $15.38	$0.00	Disclosure SEC source: 0001127430-17-000071 · edgar.xml · derivative · entry 1 STRECK PAUL · CIK 0001708063 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,210 Underlying: Common Stock · 109,210 shares Expires 2027-06-05 F1 · derivative.exercise_date: In connection with the appointment of Dr. Streck as the Company's Chief Medical Officer, the Company granted Dr. Streck an option to purchase a total of 109,210 shares of the Company's common stock. The option becomes exercisable based on the following vesting schedule: twenty-five percent (25%) vest on the first anniversary of the date of grant and twelve and one-half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Dr. Streck's continued employment with the Company on each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.